KalVista Pharmaceuticals, Inc.
KALV
$14.66
$1.148.43%
NASDAQ
| 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -38.26% | -32.69% | -14.38% | -2.04% | 12.93% |
| Gross Profit | 54.50% | 34.22% | 14.38% | 2.04% | -12.93% |
| SG&A Expenses | 110.77% | 123.81% | 106.14% | 147.00% | 117.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.85% | 29.77% | 32.20% | 44.76% | 44.07% |
| Operating Income | -19.92% | -28.86% | -32.20% | -44.76% | -44.07% |
| Income Before Tax | -32.25% | -37.10% | -39.66% | -55.53% | -52.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.28% | -41.01% | -42.34% | -59.45% | -52.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.28% | -41.01% | -42.34% | -59.45% | -52.33% |
| EBIT | -19.92% | -28.86% | -32.20% | -44.76% | -44.07% |
| EBITDA | -19.93% | -28.94% | -32.30% | -44.95% | -44.28% |
| EPS Basic | -10.46% | -9.43% | -6.59% | -16.63% | -16.99% |
| Normalized Basic EPS | -6.54% | -6.38% | -4.43% | -13.82% | -17.01% |
| EPS Diluted | -10.46% | -9.43% | -6.59% | -16.63% | -16.99% |
| Normalized Diluted EPS | -6.54% | -6.38% | -4.43% | -13.82% | -17.01% |
| Average Basic Shares Outstanding | 24.50% | 29.32% | 34.77% | 36.95% | 30.04% |
| Average Diluted Shares Outstanding | 24.50% | 29.32% | 34.77% | 36.95% | 30.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |